An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes
NCT00516048 on ClinicalTrials.gov · last registry update 2015-04-07
A small phase 3 — 58 participants, against a typical 424. The sponsor logged completion for April 2008. Primary outcome, as filed: Treatment-emergent Antibody Status (Maximum Titer Level Experienced). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 58
- Started
- 2007-08
- Primary completion
- 2008-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Treatment-emergent Antibody Status (Maximum Titer Level Experienced)
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.